the dyevert equipment is approx 350GBP per patient. No OSP don't make the dye, they make the equipment that results in approx 40% less dye used for same image quality. The result is less dye used to prevent any kidney failure issues and reduced overall costs. Even at a discount less GE sales commissions, GE are able to sell this add on to their existing customers this will result in significant growth for OSP particularly when COVID levels drop. I suspect OSP have conservative growth levels despite the GE agreement due to COVID so there is only upside and earlier cash flow positivity from here
- Forums
- ASX - By Stock
- OSP
- Ann: GE Healthcare to Distribute Osprey Medical Technology
Ann: GE Healthcare to Distribute Osprey Medical Technology, page-175
-
- There are more pages in this discussion • 257 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)